CSTONE PHARMA-B (02616) Stock Price, News, Quotes-Moomoo

HK Stock MarketDetailed Quotes

02616 CSTONE PHARMA-B

Watchlist

2.240
+0.080+3.70%

Trading Jan 20 14:44 CST

2.88BMarket Cap-18.51P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | CStone Announces Submission of Clinical Trial Application in Australia for Cs2009, an Innovative Pd-1/Vegf/Ctla-4 Trispecific Antibody
ReutersDec 22, 2024 19:00 ET
CStone Pharmaceuticals Enrolls First Patient in Phase 1B Trial for Anti-Tumor Drug
MT NewswiresDec 18, 2024 21:06 ET
CStone Pharmaceuticals (HKG:2616) Shares Fly 36% But Investors Aren't Buying For Growth
Simply Wall StDec 12, 2024 17:43 ET
CStone Pharmaceuticals Grants Commercial Rights of Tumor Drug for MENA Region to UAE Firm
MT NewswiresNov 21, 2024 03:38 ET
Express News | CStone Pharmaceuticals - CStone & Pharmalink Enter Into Strategic Partnership for Sugemalimab in Middle East, North Africa Region & South Africa
ReutersNov 20, 2024 19:01 ET
CStone Pharmaceuticals Showcases Breakthrough in Cancer Therapy
TipRanksNov 10, 2024 23:08 ET

Comments

Moomoo AI

Mar 15, 2024 17:45

CStone Pharmaceuticals' lower P/S ratio is due to its perceived limited future growth. Analysts' inferior revenue outlook contributes to its low P/S, making a significant share price rise unlikely soon.

CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%

Moomoo AI

Jan 18, 2024 16:36

CStone Pharmaceuticals' low P/S ratio is due to its poor revenue outlook. The market anticipates limited growth, paying less for the stock. These conditions form a barrier for the share price.

Why Investors Shouldn't Be Surprised By CStone Pharmaceuticals' (HKG:2616) 25% Share Price Plunge

Bamboo Works

Dec 22, 2023 01:06

Columns HBM gets health boost from drug licensing deals

HBM gets health boost from drug licensing deals
December 22, 2023
2142.HK
1.56
(-2.5%)
The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer
Key Takeaways:
Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05 billion
HBM Holdin...

Moomoo AI

Dec 4, 2023 17:32

The company's lack of profit over the last year prompts caution despite recent insider purchase showing confidence. Caution urged before investing in CStone Pharmaceuticals, despite insiders seeing potential value.

Insider Buyers At CStone Pharmaceuticals Likely Disappointed With 16% Slide

JulianMackie

Oct 21, 2021 02:24

$CSTONE PHARMA-B (02616.HK)$
Clinical approvals continue to be obtained. That's not good for the market. It becomes a bad day. That means the company will continue to burn cash. After entering shenzhen-Hong Kong stock connect, trading volume is even more depressed. Cornerstones become stepping stones. There was no agency to recommend it. Share prices have given up all this year's gains. This is cstone's darkest hour.